Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.
Clinical trial NCT05326425 · UNKNOWN
Trial details
- NCT number
- NCT05326425
- Sponsor
- Jin Hyoung Kang
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-23
- Primary completion
- 2024-06-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.